{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:47:15Z","timestamp":1781560035953,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":2814,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1111\/j.1524-4733.2005.00055.x","type":"journal-article","created":{"date-parts":[[2005,9,15]],"date-time":"2005-09-15T14:19:20Z","timestamp":1126793960000},"page":"618-628","source":"Crossref","is-referenced-by-count":20,"title":["Cost-Effectiveness of Rosuvastatin Compared with Other Statins from a Managed Care Perspective"],"prefix":"10.1016","volume":"8","author":[{"given":"Joshua S.","family":"Benner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy W.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Klingman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonothan C.","family":"Tierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Daniel","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ned","family":"Pethick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1524-4733.2005.00055.x_bib10","series-title":"2004 Heart and Stroke Statistical Update","author":"American Heart Association","year":"2003"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib20","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"The Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib30","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib40","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib50","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib60","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib70","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvistatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib80","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","article-title":"Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention","volume":"287","author":"Serruys","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib90","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/archinte.161.2.183","article-title":"Use of the statins in patients after acute myocardial infarction: does evidence change practice?","volume":"161","author":"Jackevicius","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib100","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1001\/archinte.158.16.1761","article-title":"Time trends in the use of cholesterol-lowering agents in older adults","volume":"158","author":"Lemaitre","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib110","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0002-9149(98)00227-6","article-title":"Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults","volume":"82","author":"Hoerger","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib120","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0735-1097(96)00441-X","article-title":"Variations in cholesterol management practices of U.S. physicians","volume":"29","author":"Stafford","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1161\/01.CIR.103.1.38","article-title":"Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3","volume":"103","author":"Fonarow","year":"2001","journal-title":"Circulation"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib140","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/archinte.160.4.459","article-title":"The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals","volume":"160","author":"Pearson","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib150","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0002-9149(03)00474-0","article-title":"Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events","volume":"92","author":"Foley","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib160","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1161\/01.CIR.0000066320.27195.B4","article-title":"Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999\u20132000","volume":"107","author":"Ford","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib170","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1185\/030079903125002405","article-title":"Comparison of the efficacy of rosuvastatin vs. atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial","volume":"19","author":"McKenney","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib180","series-title":"Format for Formulary Submissions, Version 2.0","author":"Academy of Managed Care Pharmacy","year":"2002"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib190","series-title":"Cost-Effectiveness in Health and Medicine","article-title":"Theoretical foundations of cost-effectiveness analysis","author":"Garber","year":"1996"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib200","series-title":"Cost-Effectiveness in Health and Medicine","article-title":"Reporting cost-effectiveness studies and results","author":"Siegel","year":"1996"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib210","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1067\/mhj.2002.128049","article-title":"Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia","volume":"144","author":"Olsson","year":"2002","journal-title":"Am Heart J"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib220","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1067\/mhj.2002.129312","article-title":"Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial","volume":"144","author":"Brown","year":"2002","journal-title":"Am Heart J"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib230","unstructured":"AstraZeneca L. Crestor\u00ae (rosuvastatin calcium) prescribing information. August 2003."},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib240","unstructured":"First Data Bank. Data on file, AstraZeneca."},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib250","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0002-9149(97)00174-4","article-title":"Comparison of one-year efficacy and safety of atorvastatin vs. lovastatin in primary hypercholesterolemia","volume":"79","author":"Davidson","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib260","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0002-9149(97)00298-1","article-title":"The rule of 5 and the rule of 7 in lipid-lowering by statin drugs[Editorial]","volume":"80","author":"Roberts","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib270","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0002-9343(01)00799-9","article-title":"Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins","volume":"111","author":"Andrews","year":"2001","journal-title":"Am J Med"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib310","doi-asserted-by":"crossref","first-page":"780","DOI":"10.7326\/0003-4819-132-10-200005160-00003","article-title":"Cost-effectiveness of 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitor therapy in older patients with myocardial infarction","volume":"132","author":"Ganz","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib320","unstructured":"First DataBank National Drug Data File. Data on file, Astra Zeneca."},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib330","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib340","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(04)16616-6","article-title":"Safety and efficacy of rosuvastatin [Letter]","volume":"364","author":"Olsson","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib350","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib360","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0272989X8500500205","article-title":"Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach","volume":"5","author":"Doubilet","year":"1985","journal-title":"Med Decis Making"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib370","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev.publhealth.23.100901.140534","article-title":"Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies","volume":"23","author":"Briggs","year":"2002","journal-title":"Annu Rev Public Health"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib380","unstructured":"Zetia\u00ae (ezetimibe) Prescribing Information. March 2003, Merck\/Schering-Plough Pharmaceuticals, Inc., Table 2."},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib390","first-page":"905","article-title":"A descriptive review of statin utilization patterns","volume":"144","author":"Fitterman","year":"2002","journal-title":"Am Heart J"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib400","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0002-9343(02)01303-7","article-title":"Statins do not meet expectation for lowering low-density lipoprotein cholesterol levels when used in clinical practice","volume":"113","author":"Frolkis","year":"2002","journal-title":"Am J Med"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib410","doi-asserted-by":"crossref","first-page":"544","DOI":"10.18553\/jmcp.2003.9.6.544","article-title":"Determinants of the cost-effectiveness of statins","volume":"9","author":"Morrison","year":"2003","journal-title":"J Manag Care Pharm"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib420","doi-asserted-by":"crossref","first-page":"81","DOI":"10.18553\/jmcp.2004.10.1.81","article-title":"Challenges in evaluating the cost-effectiveness of statins [Letter]","volume":"10","author":"Ohsfeldt","year":"2004","journal-title":"J Manag Care Pharm"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib430","doi-asserted-by":"crossref","first-page":"79","DOI":"10.18553\/jmcp.2004.10.1.79","article-title":"Evaluating the cost-effectiveness of statins[Letter]","volume":"10","author":"Hay","year":"2004","journal-title":"J Manag Care Pharm"},{"key":"10.1111\/j.1524-4733.2005.00055.x_bib440","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)","volume":"93","author":"Jones","year":"2003","journal-title":"Am J Cardiol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510678308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510678308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T15:40:16Z","timestamp":1626536416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301510678308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S1098301510678308"],"URL":"https:\/\/doi.org\/10.1111\/j.1524-4733.2005.00055.x","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}